Press & Institutional Statements
The institutional record.
Apex's external posture is held by the Office of Institutional Affairs. Press, allied institutions, and policy stakeholders are asked to use the appropriate channel below.
Releases
From the Office of Institutional Affairs.
- September 8, 2026
Apex Expands Access Program Ahead of Institutional Adoption Phase
The Restempic access program expands to accommodate institutional adoption across workforce populations.
- July 14, 2026
Apex Confirms Restempic Availability Through Access Program
Restempic (somnolyntin) is available to enrolled adults and institutional partners through the Apex access program.
- May 9, 2026
Apex Pharmaceutical Launches Apex Dispatches
A public record of the company's language, positions, and operating posture, issued by the Interim Chief Executive Officer.
Corporate boilerplate
Apex Pharmaceutical builds the infrastructure of human capacity. The company's work is organized around capacity platforms, market access language, and institutional readiness — concentrated on the categories of human limitation arriving faster than the language built to describe them. Restempic is the company's flagship capacity platform.
Apex requests that all coverage refer to the company as "Apex Pharmaceutical" on first reference and that platforms be described by name (e.g. Restempic) rather than by category alone.
Channels
- Press
Direct press inquiries through our Substack.
apexpharma.substack.com → - Restempic
Platform-specific inquiries are handled at the platform site.
restempic.com → - Institutional affairs
Stakeholder briefings and readiness engagements are arranged through the Office of the CEO and are not solicited via this site.
Media inquiries: pillars@improbable.co
Apex Pharmaceutical does not comment on unpublished research.